Ann D. Rhoads - May 27, 2022 Form 4 Insider Report for QuidelOrtho Corp (QDEL)

Role: Director
Signature: /s/ Phillip S. Askim, attorney-in-fact for Ann D. Rhoads
Stock symbol: QDEL
Transactions as of: May 27, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/1/2022, 05:39 PM
Previous filing: May 20, 2022
Next filing: Jun 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QDEL	Common Stock	Award		+2.25K			2.25K	May 27, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QDEL	Restricted Stock Units	Award	$0	+427		$0.00	427	May 27, 2022	Common Stock	427		Direct	F2, F3, F4
transaction	QDEL	Restricted Stock Units	Award	$0	+128		$0.00	128	May 27, 2022	Common Stock	128		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho.
F2	Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock.
F3	Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F4	Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.